Motivated by our results and previous reports, we tested palbociclib in vitro using mouse tumor organoids carrying loss-of-function mutations in Apc (ApcΔ716/+), an activating KrasG12D/+ mutation (hereafter referred to as AK organoids), and AK-Cdkn2a KO organoids. The gene discussed is CDKN2A; the disease is neoplasm.